HANGZHOU, China, Dec. 16, 2025 /PRNewswire/ -- Enginprime Medical Inc ("Enginprime"), an emerging leader in percutaneous ventricular assist device (pVAD) technologies and a Voyagers Capital portfolio company, today announced that its industry leading pVAD, OpusOne™, has entered its first-in-human clinical study at The Second Affiliated Hospital, School of Medicine, Zhejiang University ("SAHZU"). This milestone marks the first clinical evaluation of the device's safety and performance in patients.
PVAD supports the cardiac output via a percutaneously implanted pump, reduces the load of left ventricle, relieves heart failure symptoms, and bridges to transplantation or recovery. It also delivers temporary hemodynamic support during Complex Higher-risk Indicated Patients Percutaneous Coronary Intervention (CHIP PCI) procedures by augmenting cardiac output, preserving organ perfusion, and stabilizing hemodynamics for safe intervention. While over 60,000 pVAD procedures are performed globally each year, no pVAD product has been approved in China yet, underscoring the significant unmet medical need.
OpusOne™ features an ultra-low profile down to 8F, external durable motor placement, and an all-new design of foldable, self-expanding impeller, capable of delivering 4–5 L/min of average flow with peak flows exceeding 7 L/min. Notably, this ultra-compact device integrates invasive blood pressure monitoring and patented perfusion purification system, enabling migration detection alerts while preventing wear particles from entering the patient's body. With high durability, enhanced reliability, OpusOne™ simplifies clinical procedures, improves patient accessibility, and emerges as a highly competitive pVAD - rivaling Abiomed's Impella, Magenta's Elevate, and Supira's pVAD systems.
"Enginprime's OpusOneTM exemplified a promising approach to temporary ventricular support—especially for high-risk patients who can benefit from enhanced hemodynamic stability. Co-developed by the interventional cardiologists and Enginprime, this promising solution is tailored to address unmet clinical needs." said the study's lead investigator Jian'an Wang, MD,PhD, Director of the Cardiac Center at SAHZU. "I am impressed by its ability to achieve high flow with such a low-profile design. OpusOneTM's optimization of access and positioning options increases procedural safety."
Co-investigator of the study, Jun Jiang, MD, PhD, Executive Associate Director of the Department of Cardiology at SAHZU added, "We are pleased to perform the first procedure with OpusOneTM, seeing the patient's chest tightness was significantly alleviated. Its robust initial performance marks a meaningful advancement in circulatory support and great potential for expanding patient eligibility."
"The development of OpusOneTM reflects our mission to bring globally competitive, exceptional performance and high reliability, cost-effective next-generation circulatory support products to patients who need them most," said the CEO of Enginprime. "We look forward to advancing this innovative device rapidly through further clinical validations."
About Enginprime Medical Inc.
Enginprime was established in 2023 and incubated under majority ownership by Voyagers Capital, leveraging cross-disciplinary engineering capabilities, systems integration expertise, and advanced manufacturing methodologies. OpusOne™ is the company's first flagship medical device platform and reflects Voyagers' long-term commitment to supporting breakthrough healthcare technologies.
About Voyagers Capital
Voyagers Capital is a leading healthcare venture capital firm focused on investing in groundbreaking biotech and medtech innovation. By leveraging our expertise and network, we partner with visionary entrepreneurs to bring transformative solutions to the global market.
OpusOne™ is an investigational device, not yet approved for commercial use.
For more information, please contact:
media@enginprime.com; info@voyagerscap.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Enginprime Medical Inc Announces First-in-Human Study of Its Leading OpusOne™ pVAD
Celebrating the Tournament's 50th Anniversary
HONG KONG, April 2, 2026 /PRNewswire/ -- Marriott Bonvoy, Marriott International's award-winning travel platform, today announced a renewed partnership with Hong Kong China Rugby (HKCR) to serve as an Official Partner of the Cathay/HSBC Hong Kong Sevens 2026. The partnership marks Marriott Bonvoy's return to one of the city's most iconic sporting events after previously partnering with the tournament from 2016 to 2019. The reunion also coincides with the 50th anniversary of the Hong Kong Sevens, celebrating five decades of world-class rugby, vibrant fan experiences, and the unifying power of sport.
The Cathay/HSBC Hong Kong Sevens 2026 will take place at Kai Tak Sports Park from 17 – 19 April 2026, bringing together the world's best rugby sevens teams and passionate fans from around the globe.
Building on its role as a Founding Partner of Kai Tak Sports Park, Marriott Bonvoy's return to the Hong Kong Sevens underscores the brand's enduring connection to Hong Kong's sporting heritage and commitment to inspiring travel through passion points like sport—empowering travellers to pursue what they love while connecting with a global community of fans.
"We are thrilled to return to the Hong Kong Sevens in its landmark 50th year," said Betty Tian, Managing Vice President, Customer, Greater China, Marriott International. "Shared passion for sport brings people together in powerful ways, uniting fans across cultures, generations, and geographies. As a lifelong travel partner, Marriott Bonvoy is proud to create experiences that bring fans closer to the energy of Hong Kong's most iconic events and to one another, turning meaningful moments into lasting memories for travellers at every step of their journeys."
Throughout the tournament, Marriott Bonvoy will elevate the fan experience with member-exclusive hospitality offerings and Marriott Bonvoy Moments™, providing members the opportunity to redeem their points for exclusive and VIP access to the tournament. Members can redeem points for full-day access to the Marriott Bonvoy Suite in Kai Tak Stadium, where curated food and beverage offerings will be served during the matches. Members can also look forward to surprise visits from legendary rugby players as arranged by Hong Kong China Rugby, bringing them closer to the sport they love.
"We are delighted to welcome Marriott Bonvoy back into the Hong Kong Sevens family," added Bryan Rennie, Executive Director, Commercial and Business Operations, Hong Kong China Rugby. "As we celebrate 50 years of rugby tradition, their renewed support underscores our shared commitment to creating world-class experiences that unite the sporting and hospitality communities."
About Marriott Bonvoy®
Marriott Bonvoy, Marriott International's award-winning travel platform, connects travelers to the people, places, and passions they love through an extraordinary collection of hotels and experiences worldwide. The platform features over 30 hotel brands and 10,000 destinations, including the largest collection of luxury offerings, distinctive boutique properties, premium home rentals, and more, providing renowned hospitality across the globe. With unrivaled access to the best in entertainment, culinary, sports, outdoor adventure, arts, culture, and more, Marriott Bonvoy offers transformative travel experiences that leave a lasting impression.
Marriott Bonvoy membership is free and unlocks unique benefits including the ability to earn points through travel and everyday activities, like purchases with co-branded credit cards. Members can redeem their points for free stays, experiences and more. Visit marriottbonvoy.com for more information and download the Marriott Bonvoy app here. Travelers can connect with Marriott Bonvoy on Instagram, TikTok, YouTube, and Facebook.
About Hong Kong China Rugby
About HKCR Established in 1952, HKCR is the governing body for rugby in Hong Kong and a full member of World Rugby and the Sports Federation & Olympic Committee of Hong Kong, China. Over the past 70 years HKCR has built a reputation in the international sports sector for innovation, excellence, community engagement and exemplary governance.
About the Cathay/HSBC Hong Kong Sevens
Established in 1976 and organised annually by Hong Kong China Rugby, the Hong Kong Sevens is the world's premier international sevens event. Since 1999, the Hong Kong Sevens has been a part of World Rugby's HSBC SVNS Series.
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Marriott Bonvoy Returns as an Official Partner of the Cathay/HSBC Hong Kong Sevens 2026
